Staff View
Cross talk between macrophages and glioma stem cells

Descriptive

TitleInfo
Title
Cross talk between macrophages and glioma stem cells
Name (type = personal)
NamePart (type = family)
Nusblat
NamePart (type = given)
Leora Molly
NamePart (type = date)
1983-
DisplayForm
Leora Nusblat
Role
RoleTerm (authority = RULIB)
author
Name (type = personal)
NamePart (type = family)
Roth
NamePart (type = given)
Charles M
DisplayForm
Charles M Roth
Affiliation
Advisory Committee
Role
RoleTerm (authority = RULIB)
chair
Name (type = personal)
NamePart (type = family)
Yarmush
NamePart (type = given)
Martin l
DisplayForm
Martin l Yarmush
Affiliation
Advisory Committee
Role
RoleTerm (authority = RULIB)
internal member
Name (type = personal)
NamePart (type = family)
Cai
NamePart (type = given)
Li
DisplayForm
Li Cai
Affiliation
Advisory Committee
Role
RoleTerm (authority = RULIB)
internal member
Name (type = personal)
NamePart (type = family)
Glod
NamePart (type = given)
John W
DisplayForm
John W Glod
Affiliation
Advisory Committee
Role
RoleTerm (authority = RULIB)
outside member
Name (type = corporate)
NamePart
Rutgers University
Role
RoleTerm (authority = RULIB)
degree grantor
Name (type = corporate)
NamePart
Graduate School - New Brunswick
Role
RoleTerm (authority = RULIB)
school
TypeOfResource
Text
Genre (authority = marcgt)
theses
OriginInfo
DateCreated (qualifier = exact)
2014
DateOther (qualifier = exact); (type = degree)
2014-10
CopyrightDate (encoding = w3cdtf)
2014
Place
PlaceTerm (type = code)
xx
Language
LanguageTerm (authority = ISO639-2b); (type = code)
eng
Abstract (type = abstract)
Given its extremely poor prognosis, there is a pressing need for improved understanding of the biology of glioblastoma multiforme (GBM), including the roles of tumor subpopulations, such as macrophages, that contribute to tumor growth and therapeutic resistance. DNA alkylating agents, such as temozolomide and carmustine, are the current gold standard drug treatment for GBM, yet resistance occurs and is attributable to a subset of cancer stem cells (CSCs). The mechanisms by which the CSC state is produced and promotes drug resistance are not well understood, but molecular pathways are beginning to emerge. We investigated the interplay between CSCs and macrophages via co-culture. The results showed that macrophages communicate with and influence CSC functions via a paracrine loop. Specifically, the levels of an M2 macrophage-specific secreted cytokine, TGF-β1, were elevated in the presence of CSCs, but whether the cells were plated as contacting or non-contacting co-cultures did not affect the results. Furthermore, co-culturing with CSCs resulted in enhanced expression of M2 markers in macrophages that were previously polarized to the M1 phenotype. A major player in the cross talk is the inflammatory transcription factor, STAT3, produced by CSCs, which recruits and subsequently modulates macrophages to become immunosuppressive, maintaining CSC stemness. Another intriguing target is the transcription factor, HIF-2α, the expression of which is markedly increased in hypoxic CSCs. Here, we utilized short interfering RNA (siRNA) to silence CSC targets. For the delivery of siRNA cargo, cationic amphiphilic macromolecule (CAM) – lipid complexes were co-developed. We discovered that addition of certain levels of lipid induces pH-dependent instabilities that promote intracellular delivery and release from endosomes, leading to efficient gene silencing. We utilized these CAM-lipid complexes or Lipofectamine for silencing experiments. It was observed in both glioblastoma patient and cell line-derived CSCs that neurosphere formation, proliferation rate, chemoresistance, migration towards macrophage conditioned media, and matrix degradation were elevated compared to bulk tumor. Addition of STAT3 siRNA potentiated modestly the effects of carmustine on CSCs. HIF-2α siRNA had a significant effect on hypoxic CSC functions and induced their differentiation. Thus, disrupting CSC stemness or their cross talk with macrophages may be viable avenues for next-generation cancer therapeutics.
Subject (authority = RUETD)
Topic
Biomedical Engineering
Subject (authority = ETD-LCSH)
Topic
Glioblastoma multiforme
Subject (authority = ETD-LCSH)
Topic
Macrophages
Subject (authority = ETD-LCSH)
Topic
Stem cells
RelatedItem (type = host)
TitleInfo
Title
Rutgers University Electronic Theses and Dissertations
Identifier (type = RULIB)
ETD
Identifier
ETD_5988
PhysicalDescription
Form (authority = gmd)
electronic resource
InternetMediaType
application/pdf
InternetMediaType
text/xml
Extent
1 online resource (x, 59 p. : ill.)
Note (type = degree)
Ph.D.
Note (type = bibliography)
Includes bibliographical references
Note (type = statement of responsibility)
by Leora Molly Nusblat
RelatedItem (type = host)
TitleInfo
Title
Graduate School - New Brunswick Electronic Theses and Dissertations
Identifier (type = local)
rucore19991600001
Location
PhysicalLocation (authority = marcorg); (displayLabel = Rutgers, The State University of New Jersey)
NjNbRU
Identifier (type = doi)
doi:10.7282/T3CF9PCM
Genre (authority = ExL-Esploro)
ETD doctoral
Back to the top

Rights

RightsDeclaration (ID = rulibRdec0006)
The author owns the copyright to this work.
RightsHolder (type = personal)
Name
FamilyName
Nusblat
GivenName
Leora
MiddleName
Molly
Role
Copyright Holder
RightsEvent
Type
Permission or license
DateTime (encoding = w3cdtf); (qualifier = exact); (point = start)
2014-10-01 11:10:50
AssociatedEntity
Name
Leora Nusblat
Role
Copyright holder
Affiliation
Rutgers University. Graduate School - New Brunswick
AssociatedObject
Type
License
Name
Author Agreement License
Detail
I hereby grant to the Rutgers University Libraries and to my school the non-exclusive right to archive, reproduce and distribute my thesis or dissertation, in whole or in part, and/or my abstract, in whole or in part, in and from an electronic format, subject to the release date subsequently stipulated in this submittal form and approved by my school. I represent and stipulate that the thesis or dissertation and its abstract are my original work, that they do not infringe or violate any rights of others, and that I make these grants as the sole owner of the rights to my thesis or dissertation and its abstract. I represent that I have obtained written permissions, when necessary, from the owner(s) of each third party copyrighted matter to be included in my thesis or dissertation and will supply copies of such upon request by my school. I acknowledge that RU ETD and my school will not distribute my thesis or dissertation or its abstract if, in their reasonable judgment, they believe all such rights have not been secured. I acknowledge that I retain ownership rights to the copyright of my work. I also retain the right to use all or part of this thesis or dissertation in future works, such as articles or books.
Copyright
Status
Copyright protected
Availability
Status
Open
Reason
Permission or license
Back to the top

Technical

RULTechMD (ID = TECHNICAL1)
ContentModel
ETD
OperatingSystem (VERSION = 5.1)
windows xp
Back to the top
Version 8.5.5
Rutgers University Libraries - Copyright ©2024